Baril JG et al.15, 2007. Canada |
Clinical Trial, randomized, controlled, crossover. 24 weeks (author). 12 weeks (used). |
Salmon oil. EPA/DHA - 540/360mg. n = 26 |
Did not use placebo, did not receive oil (salmon) in the 12 initial weeks, but from 12th -24th weeks. n = 31 |
3 |
I
|
C
|
mg/dL(SD)
|
mmol/L(SD)
|
mg/dL(SD)
|
mmol/L(SD)
|
380,5 (203,5), reduction TG. P = 0.04 |
4.3 (2.3) |
433.6 (212.3) |
4.9 (2.4) |
Peters BS et al.26, 2012. England |
Clinical trial, randomized Double-blind, controlled. 12 weeks. |
Hypocholesterinic diet in use of fibrate or niacin. Omacor®. EPA/DHA - 1840/1520mg. n = 23 |
Hypocholesterinic diet in use of fibrate or niacin + placebo. n = 25 |
5 |
I
|
C
|
mg/dL (SD)
|
mmol/L (SD)
|
mg/dL (SD)
|
mmol/L(SD)
|
342.4 (168.1), reduction TG. p = 0.02 |
3.78 (1.90) |
425.6 (272.5) |
4.81 (3.08) |
Carter et al.25, 2006. Australia |
Clinical trial, randomized Double-blind, controlled. 14 weeks. |
Maxepa®. EPA/DHA - 1620/1080mg. n = 5 |
Dietary guidance for 6 weeks (NHFG) placebo (olive oil). n = 6 |
4 |
I
|
C
|
mg/dL (SD)
|
mmol/L (SD)
|
mg/dL (SD)
|
mmol/L(SD)
|
203.5 (163.7), reduction TG. p = 0.04 |
2.3 (1.85) |
361.1(163.7) |
4.08 (1.85) |
De Truchis et al.27, 2007. France |
Clinical trial, randomized Double-blind, controlled. crossover. 16 weeks (author). 8 weeks (used). |
Maxepa® EPA/DHA - 1080mg/720mg. n = 58 |
4 weeks diet (AHA) placebo. n = 62 |
5 |
I
|
C
|
mg/dL (SD)
|
mmol/L (SD)
|
mg/dL (SD)
|
mmol/L (SD)
|
340 (180), reduction TG. p = 0.003 |
3.8 (2.30) |
480 (310) |
5.4 (3.5) |
Wohl et al.28, 2005. USA |
Clinical Trial, randomized, controlled. 16 weeks (author). 4 weeks (used). |
Coromega®. EPA/DHA - 1750/1150mg. n = 24. |
Diet and physical activity (AHA), no placebo. n = 20 |
3 |
I
|
C
|
mg/dL (SD)
|
mmol/L (SD)
|
mg/dL (SD)
|
mmol/L (SD)
|
306 (162), redução TG. p = 0,007 |
3.4 (1.8) |
503 (421) |
5.6 (4.7) |
Thusgaardet al..29, 2009. Denmark |
Clinical trial, randomized Double-blind, controlled. 12 weeks. |
Omacor® EPA/DHA - 1840/1520mg. n = 25 |
Placebo, 2 pills, 2g corn oil 2x/day. n = 23 |
4 |
I
|
C
|
mg/dL (SD)
|
mmol/L (SD)
|
mg/dL (SD)
|
mmol/L (SD)
|
134.5 (85.8), reduction TG. p = 0.03 |
1.52 (0.97) |
178.7 (170.7) |
2.02 (1.93) |
Capili & Anastasi17, 2013. USA |
Clinical trial, randomized Double-blind, controlled. 10 weeks (author). 8 weeks (used). |
Diet (NCEP-TLC). Fish oil. EPA/DHA - 2400mg/1600mg n = 8 |
Diet (NCEP-TLC) placebo n = 10 |
4 |
I
|
C
|
mg/dL (SD)
|
mmol/L (SD)
|
mg/dL (SD)
|
mmol/L (SD)
|
169 (133), reduction TG. p = 0.013 |
1.90 (1.50) |
289 (129) |
3.26 (1.45) |
Oliveira et al.16, 2014. Brazil |
Clinical Trial, randomized, controlled. 24 weeks. |
Fish oil. EPA/DHA - 540mg/365mg. n = 31 |
Placebo, 3g soy oil/day n = 35 |
3 |
I
|
C
|
mg/dL (SD)
|
mmol/L (SD)
|
mg/dL (SD)
|
mmol/L (SD)
|
141.7 (59.7), Non-significant reduction TG When compared with GC. p = 0.613 |
1.60 (0.67) |
158.6 (59.0) |
1.79 (0.66) |
Paranandi A et al.14, 2014. USA |
Clinical Trial, randomized, controlled. Crossover. 28 weeks (author) Washout (4 weeks) 12 weeks (used). |
Lovaza®. EPA/DHA - 1860/1500mg (12 weeks) n = 17 |
Placebo (12 weeks.), washout (4 weeks) and 4 pills of Lovaza® (12 weeks). n = 19 |
5 |
I
|
C
|
mg/dL (SD)
|
mmol/L (SD)
|
mg/dL (SD)
|
mmol/L (SD)
|
215.6 (149.4), reduction TG. p = 0.001 |
2.43 (1.68) |
335.6 (314.2) |
3.79 (3.55) |